John F. Tisdale
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
John F. Tisdale has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- Selami Demirci
Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute/National Institutes of Health, Bethesda, MD
8 shared publications Alexis Leonard
Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute/National Institutes of Health, Bethesda, MD
6 shared publicationsKhaled Essawi
Department of Medical Laboratory Technology, College of Applied Medical Sciences, Jazan University, Gizan 45142, Saudi Arabia
5 shared publicationsNaoya Uchida
National Heart, Lung, and Blood Institute (NHLBI)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), Bethesda, MD 20814, USA
4 shared publicationsAllen E. Krouse
Translational Stem Cell Biology Branch, NHLBI, NIH, Bethesda, MD 20814, USA
3 shared publicationsAylin C. Bonifacino
Translational Stem Cell Biology Branch, NHLBI, NIH, Bethesda, MD 20814, USA
3 shared publications
Latest Publications
- Open Access
- 14 January 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (2) , 289-300
Comparative analysis of CRISPR-Cas9, lentiviral transduction, and base editing for sickle cell disease in a murine model
Sickle cell disease (SCD) is a red blood cell disorder caused by a mutation in the β-globin gene, leading to sickle hemoglobin polymerization under low oxygen conditions. Both CRISPR-Cas9 editing and lentiviral transduction have shown promising clinical outcomes, but it remains unclear which approach is superior. Alternatively, new editing tools such as base editing may also be promising and reduce risks of genotoxicity. To compare these approaches, we studied them in an immunocompromised mouse model. We optimized ex vivo conditions in CD34+ hematopoietic stem and progenitor cells (HSPC) and infused edited SCD HSPC into busulfan-conditioned nonirradiated NOD,B6.SCID Il2rγ−/−KitW41/W41 (NBSGW) mice. Ex vivo analysis confirmed successful editing and transduction. At 16 weeks, bone marrow analysis showed similar human CD45+ cell engraftment across all groups (75%-90%). In the competitive transplantation group, there was a lower amount of B-cell lymphoma/leukemia 11A enhancer editing than base editing and lentiviral transduction. A secondary transplantation model yielded similar results. An antisickling assay showed significantly higher red blood cell sickling reduction in the base editing, transduction, and competitive transplantation groups compared to CRISPR-Cas9. In conclusion, although all methods showed therapeutic potential, base editing and lentiviral transduction provided superior outcomes over CRISPR-Cas9–mediated editing in a competitive murine transplantation model.
- 14 January 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (2) , 289-300
Open AccessComparative analysis of CRISPR-Cas9, lentiviral transduction, and base editing for sickle cell disease in a murine model
Sickle cell disease (SCD) is a red blood cell disorder caused by a mutation in the β-globin gene, leading to sickle hemoglobin polymerization under low oxygen conditions. Both CRISPR-Cas9 editing and lentiviral transduction have shown promising clinical outcomes, but it remains unclear which approach is superior. Alternatively, new editing tools such as base editing may also be promising and reduce risks of genotoxicity. To compare these approaches, we studied them in an immunocompromised mouse model. We optimized ex vivo conditions in CD34+ hematopoietic stem and progenitor cells (HSPC) and infused edited SCD HSPC into busulfan-conditioned nonirradiated NOD,B6.SCID Il2rγ−/−KitW41/W41 (NBSGW) mice. Ex vivo analysis confirmed successful editing and transduction. At 16 weeks, bone marrow analysis showed similar human CD45+ cell engraftment across all groups (75%-90%). In the competitive transplantation group, there was a lower amount of B-cell lymphoma/leukemia 11A enhancer editing than base editing and lentiviral transduction. A secondary transplantation model yielded similar results. An antisickling assay showed significantly higher red blood cell sickling reduction in the base editing, transduction, and competitive transplantation groups compared to CRISPR-Cas9. In conclusion, although all methods showed therapeutic potential, base editing and lentiviral transduction provided superior outcomes over CRISPR-Cas9–mediated editing in a competitive murine transplantation model.
- Open Access
- 1 April 2025
- Published by Elsevier in Molecular Therapy
- Vol. 33 (5) , 2154-2171
Genome editing strategies for targeted correction of β-globin mutation in sickle cell disease: From bench to bedside
- 1 April 2025
- Published by Elsevier in Molecular Therapy
- Vol. 33 (5) , 2154-2171
Open AccessGenome editing strategies for targeted correction of β-globin mutation in sickle cell disease: From bench to bedside
- Top Cited PapersOpen Access
- 20 March 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (3) , 758
Scientific Advancements in Gene Therapies: Opportunities for Global Regulatory Convergence
On 4 September 2024, the Reagan-Udall Foundation for the FDA (FDA Foundation) in collaboration with the Food and Drug Administration (FDA) and the Gates Foundation hosted a workshop titled “Scientific Advancements in Gene Therapies: Opportunities for Global Regulatory Convergence”. The event brought together a diverse group of experts, including international regulatory bodies, regulated industries, healthcare professionals, patients, academic researchers and global health advocates, to discuss the rapid advancements in gene therapy and the pressing need for equitable access in low-and middle-income countries (LMICs), with sickle cell disease (SCD) serving as the model disorder for the discussions. Although there has been significant progress in gene therapy, such as breakthroughs in clustered regularly interspaced short palindromic repeats (CRISPR)-based technologies and FDA-approved therapies, access to these therapies remain limited in underresourced regions. The workshop addressed critical challenges, including the high cost of therapies, regulatory gaps and barriers and ethical concerns regarding informed consent and public engagement in LMICs. This paper highlights the critical discussion points from the workshop with a focus on exploring strategies for global regulatory convergence, the role of international collaborations and the potential pathways to making gene therapies affordable and accessible to all.
- 20 March 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (3) , 758
Top Cited PapersOpen AccessScientific Advancements in Gene Therapies: Opportunities for Global Regulatory Convergence
On 4 September 2024, the Reagan-Udall Foundation for the FDA (FDA Foundation) in collaboration with the Food and Drug Administration (FDA) and the Gates Foundation hosted a workshop titled “Scientific Advancements in Gene Therapies: Opportunities for Global Regulatory Convergence”. The event brought together a diverse group of experts, including international regulatory bodies, regulated industries, healthcare professionals, patients, academic researchers and global health advocates, to discuss the rapid advancements in gene therapy and the pressing need for equitable access in low-and middle-income countries (LMICs), with sickle cell disease (SCD) serving as the model disorder for the discussions. Although there has been significant progress in gene therapy, such as breakthroughs in clustered regularly interspaced short palindromic repeats (CRISPR)-based technologies and FDA-approved therapies, access to these therapies remain limited in underresourced regions. The workshop addressed critical challenges, including the high cost of therapies, regulatory gaps and barriers and ethical concerns regarding informed consent and public engagement in LMICs. This paper highlights the critical discussion points from the workshop with a focus on exploring strategies for global regulatory convergence, the role of international collaborations and the potential pathways to making gene therapies affordable and accessible to all.
- 5 December 2024
- Published by Elsevier in Cell Stem Cell
- Vol. 32 (2) , 209-226.e8
BCL11A +58/+55 enhancer-editing facilitates HSPC engraftment and HbF induction in rhesus macaques conditioned with a CD45 antibody-drug conjugate
- 5 December 2024
- Published by Elsevier in Cell Stem Cell
- Vol. 32 (2) , 209-226.e8
BCL11A +58/+55 enhancer-editing facilitates HSPC engraftment and HbF induction in rhesus macaques conditioned with a CD45 antibody-drug conjugate
- 24 February 2024
- Published by Elsevier in Cytotherapy
- Vol. 26 (6) , 641-648
Ex vivo culture resting time impacts transplantation outcomes of genome-edited human hematopoietic stem and progenitor cells in xenograft mouse models
- 24 February 2024
- Published by Elsevier in Cytotherapy
- Vol. 26 (6) , 641-648
Ex vivo culture resting time impacts transplantation outcomes of genome-edited human hematopoietic stem and progenitor cells in xenograft mouse models
- Open Access
- 20 April 2023
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 29, 483-493
Pre-existing immunity does not impair the engraftment of CRISPR-Cas9-edited cells in rhesus macaques conditioned with busulfan or radiation
- 20 April 2023
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 29, 483-493
Open AccessPre-existing immunity does not impair the engraftment of CRISPR-Cas9-edited cells in rhesus macaques conditioned with busulfan or radiation
- 1 October 2022
- Published by SAGE Publications in The CRISPR Journal
- Vol. 5 (5) , 660-676
Advances in CRISPR Delivery Methods: Perspectives and Challenges
With the advent of new genome editing technologies and the emphasis placed on their optimization, the genetic and phenotypic correction of a plethora of diseases sit on the horizon. Ideally, genome editing approaches would provide long-term solutions through permanent disease correction instead of simply treating patients symptomatically. Although various editing machinery options exist, the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas (CRISPR-associated protein) editing technique has emerged as the most popular due to its high editing efficiency, simplicity, and affordability. However, while CRISPR technology is gradually being perfected, optimization is futile without accessible, effective, and safe delivery to the desired cell or tissue. Therefore, it is important that scientists simultaneously focus on inventing and improving delivery modalities for editing machinery as well. In this review, we will discuss the critical details of viral and nonviral delivery systems, including payload, immunogenicity, efficacy in delivery, clinical application, and future directions.
- 1 October 2022
- Published by SAGE Publications in The CRISPR Journal
- Vol. 5 (5) , 660-676
Advances in CRISPR Delivery Methods: Perspectives and Challenges
With the advent of new genome editing technologies and the emphasis placed on their optimization, the genetic and phenotypic correction of a plethora of diseases sit on the horizon. Ideally, genome editing approaches would provide long-term solutions through permanent disease correction instead of simply treating patients symptomatically. Although various editing machinery options exist, the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas (CRISPR-associated protein) editing technique has emerged as the most popular due to its high editing efficiency, simplicity, and affordability. However, while CRISPR technology is gradually being perfected, optimization is futile without accessible, effective, and safe delivery to the desired cell or tissue. Therefore, it is important that scientists simultaneously focus on inventing and improving delivery modalities for editing machinery as well. In this review, we will discuss the critical details of viral and nonviral delivery systems, including payload, immunogenicity, efficacy in delivery, clinical application, and future directions.
- Open Access
- 1 October 2021
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 23, 276-285
CRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell disease
- 1 October 2021
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 23, 276-285
Open AccessCRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell disease
- Open Access
- 1 April 2021
- Published by Elsevier in Molecular Therapy
- Vol. 29 (4) , 1355-1356
A pause in gene therapy: Reflecting on the unique challenges of sickle cell disease
- 1 April 2021
- Published by Elsevier in Molecular Therapy
- Vol. 29 (4) , 1355-1356
Open AccessA pause in gene therapy: Reflecting on the unique challenges of sickle cell disease
- 1 February 2021
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 60 (1) , 103057
Allogenic hematopoietic stem cell transplantation in sickle cell disease
- 1 February 2021
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 60 (1) , 103057
Allogenic hematopoietic stem cell transplantation in sickle cell disease